Expression of LHFPL2 in hepatocellular carcinoma and its association with prognosis after transarterial chemoembolization

doi:10.4240/wjgs.116682

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(2)

(3)

(0)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Surg. Jun 27, 2026; 18(6): 116682
Published online Jun 27, 2026. doi: 10.4240/wjgs.116682

Open in New Tab Full Size Figure Download Figure

Figure 1 Representative immunohistochemical staining of lipoma HMGIC fusion partner-like 2 expression in transarterial chemoembolization-resistant and non-resistant groups. A: Transarterial chemoembolization-resistant group; B: Non-resistant group.

Open in New Tab Full Size Figure Download Figure

Figure 2 Correlation curve between lipoma HMGIC fusion partner-like 2 expression and patient survival. LHFPL2: Lipoma HMGIC fusion partner-like 2.

Open in New Tab Full Size Figure Download Figure

Figure 3 Forest plot of the multivariate Cox regression analysis for factors influencing patient survival prognosis. CI: Confidence interval; HR: Hazard ratio; TACE: Transarterial chemoembolization; LHFPL2: Lipoma HMGIC fusion partner-like 2; AFP: Alpha-fetoprotein.

Open in New Tab Full Size Figure Download Figure

Figure 4 Survival curves of patients with hepatocellular carcinoma in the lipoma HMGIC fusion partner-like 2-alpha-fetoprotein combination group. LHFPL2: Lipoma HMGIC fusion partner-like 2; AFP: Alpha-fetoprotein.

Citation: Sun L, Chen K, Zhu XL. Expression of LHFPL2 in hepatocellular carcinoma and its association with prognosis after transarterial chemoembolization. World J Gastrointest Surg 2026; 18(6): 116682
URL: https://www.wjgnet.com/1948-9366/full/v18/i6/116682.htm
DOI: https://dx.doi.org/10.4240/wjgs.116682

Sun L, Chen K, Zhu XL. Expression of LHFPL2 in hepatocellular carcinoma and its association with prognosis after transarterial chemoembolization. World J Gastrointest Surg 2026; 18(6): 116682 [DOI: 10.4240/wjgs.116682]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.